OrthoPediatrics (KIDS) Stock Price, News & Analysis

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OrthoPediatrics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KIDS shares.
View KIDS analyst ratings or view top-rated stocks.

4 Wall Street research analysts have issued 12-month price targets for OrthoPediatrics' shares. Their KIDS share price targets range from $38.00 to $52.00. On average, they expect the company's share price to reach $45.50 in the next twelve months. This suggests a possible upside of 46.3% from the stock's current price.
View analysts price targets for KIDS or view top-rated stocks among Wall Street analysts.

OrthoPediatrics' stock was trading at $32.51 at the beginning of the year. Since then, KIDS stock has decreased by 4.4% and is now trading at $31.09.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024.
View our KIDS earnings forecast.

OrthoPediatrics Corp. (NASDAQ:KIDS) issued its earnings results on Wednesday, March, 6th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.05. The firm earned $37.61 million during the quarter, compared to analyst estimates of $37.59 million. OrthoPediatrics had a negative net margin of 13.58% and a negative trailing twelve-month return on equity of 5.12%.

OrthoPediatrics issued an update on its FY 2024 earnings guidance on Monday, May, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.0 million-$203.0 million, compared to the consensus revenue estimate of $198.1 million.

15 employees have rated OrthoPediatrics Chief Executive Officer Mark Throdahl on Glassdoor.com. Mark Throdahl has an approval rating of 100% among the company's employees. This puts Mark Throdahl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other OrthoPediatrics investors own include AbbVie (ABBV), Freeport-McMoRan (FCX), Gilead Sciences (GILD), Intel (INTC), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Cisco Systems (CSCO), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

OrthoPediatrics (KIDS) raised $52 million in an initial public offering on Thursday, October 12th 2017. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Piper and Jaffray Stifel served as the underwriters for the IPO and William Blair and BTIG were co-managers.

OrthoPediatrics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.72%), Wasatch Advisors LP (2.11%), Riverbridge Partners LLC (2.07%), Conestoga Capital Advisors LLC (0.20%), Mutual of America Capital Management LLC (0.16%) and Blue Trust Inc. (0.11%). Insiders that own company stock include (Reynolds) Marie C Infante, Bernie B Berry III, Daniel J Gerritzen, David R Bailey, Fred Hite, Gregory A Odle, Harold Ruf, Jennifer N Pritzker, Joseph W Hauser, Mark C Throdahl, Stephen F Burns and Terry D Schlotterback.
View institutional ownership trends.

Shares of KIDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.